Hola,
Are you new here?

VASA

financed

Vaccine Against Schistosomiasis for Africa. A Phase I clinical study of the Schi...

Vaccine Against Schistosomiasis for Africa. A Phase I clinical study of the SchistoShield anti schistosomiasis vaccine in adults in endemic areas of sub Saharan Africa Schistosomiasis is a poverty-related neglected tropical disease, impacting one billion people in 74 countries. Science ranked a schistosomiasis-vaccine as one of the top-10 vaccines urgently needed. Chemotherapy is the preferred m... see more

31/03/2026

THE CHANCELLOR MAS...

7M€

Project Budget: 7M€

Project leader

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 13 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2019-05-06

SC1-BHC-15-2018: New anti-infective agents for preve... Specific Challenge:Neglected Infectious Diseases (NIDs) diseases are responsible for a significant h...

I+D

Cerrada does 7 years

0% 100% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

13 Participantes

THE CHANCELLOR MASTERS AND S...

1.32M€ | Leader

3M ESPAÑA

262.07K€ | participant

41.25K€ | participant

UGOT - GOETEBORGS UNIVERSITE...

380.00K€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 82 months Date Start: 2019-05-06
End date: 2026-03-31

Project leader

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 7M€

participation deadline Sin fecha límite de participación.

Project description Schistosomiasis is a poverty-related neglected tropical disease, impacting one billion people in 74 countries. Science ranked a schistosomiasis-vaccine as one of the top-10 vaccines urgently needed. Chemotherapy is the preferred method for schistosomiasis control; but the effectiveness of mass-treatment programs is compromised by reinfection requiring regular re-treatment. An efficacious vaccine, with long-lasting protection against all schistosomiasis forms, would impact disease control. We request funding for the clinical development of our SchistoShield®-vaccine (Sm- p80 antigen+GLA-SE adjuvant) in Burkina Faso and Madagascar, where Schistosoma mansoni (causing intestinal/ hepatic schistosomiasis) and S. haematobium (causing urinary schistosomiasis) are endemic. In baboon studies, SchistoShield® has been effective against all major schistosome species. It is the only vaccine candidate having consistently exhibited potent prophylactic, anti-fecundity, egg-induced pathology resolving, transmission-blocking and therapeutic efficacy. The objectives are to 1) assess the safety/immunogenicity of SchistoShield® in a Phase I clinical study in healthy adults from Africa; 2) refine and develop a female worm schistosome human challenge model; 3) identify correlates of protection, innate and adaptive immune signatures, gene expression and the role of antibodies in the prevention/control of Schistosoma infections; and 4) foster a global consortium to advance research on schistosomiasis disease burden, vaccines and address downstream access constraints in resource-poor settings. The funding requested will allow the clinical development of SchistoShield®. African site research capacity will be improved and epidemiological burden data using novel diagnostic techniques will be used to advance clinical development to Phase 2 and potential future elimination project

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers